MOLECULAR GENETIC EVENTS IN LUNG CANCER

A. 小细胞肺癌患者的66个肿瘤细胞系 已研究用于myc家族DNA扩增。 35中的15 (43%）从先前处理的小细胞建立的细胞系 肺癌患者扩增为myc家族之一 与3/30（10%）的细胞系相比， 未经治疗的患者 小细胞肺癌的化疗 肿瘤细胞系有c-myc家族DNA扩增的患者 中位寿命为27周，而 肿瘤细胞系不具有c-myc家族DNA扩增。 从小细胞肺癌患者中收集的38个肿瘤 已研究用于myc家族DNA扩增。 38中的6个 (16%）具有癌基因myc家族之一的DNA扩增 N-myc 4例，L-myc 2例。 所有这些都是从化疗中获得的 治疗小细胞肺癌患者。 myc家族DNA 扩增似乎更常见于化疗治疗 小细胞癌患者和c-myc家族DNA扩增是 与生存期缩短有关。 B。 限制性片段长度多态性（RFLP）研究 35名小细胞肺癌患者中有33名 肿瘤组织DNA中存在的杂合性， 组织DNA 这证实了遗传信息的丢失 定位于3号染色体的短臂，先前由 核型分析 肺外小细胞癌已经 使用核型和RFLP分析进行研究，4/5的患者保留了 两种RFLP分析均在3 p14 -21区域 和核型分析。 这表明了一种不同的基因 组织学上无法区分的肿瘤病变。

A. Sixty-six tumor cell lines from small cell-lung cancer patients have been studied for myc family DNA amplification. Fifteen of 35 (43%) cell lines established from previously treated small cell lung cancer patients have been amplified for one of the myc family genes compared to 3/30 (10%) of cell lines established from untreated patients. Chemotherapy treated small cell lung cancer patients whose tumor cell lines have c-myc family DNA amplification live a median of 27 weeks compared to 49 weeks for patients whose tumor cell lines do not have c-myc family DNA amplification. Thirty-eight tumors harvested from small cell lung cancer patients have been studied for myc family DNA amplification. Six of 38 (16%) have DNA amplification of one of the myc family of oncogenes (4 N-myc and 2 L-myc). All these were obtained from chemotherapy treated small cell lung cancer patients. myc family DNA amplification appears to be more common in chemotherapy treated small cell cancer patients and c-myc family DNA amplification is associated with shortened survival. B. Restriction fragment length polymorphism (RFLP) studies have shown that 33 of 35 patients with small cell lung cancer lose heterozygosity in the tumor tissue DNA that was present in normal tissue DNA. This confirms the loss of genetic information localized to the short arm of chromosome 3 previously described by karyotype analysis. Extrapulmonary small cell cancers have been studied using karyotype and RFLP analysis and 4/5 patients retain both chromosome 3's in the region of 3p14-21 by both RFLP analysis and karyotype analysis. This demonstrates a different genetic lesion in tumors that histologically are indistinguishable.